- Glioblastoma multiforme (brain cancer)
- Persistent, recurrent, or metastatic breast cancer
- Metastatic cervical cancer
- Advanced kidney cancer
- Metastatic colorectal cancer
- Advanced non-small-cell lung cancer
- Liver Cancer- Hepatocellular carcinoma
- Cancers of the ovary, cervical, fallopian tube, or primary peritoneal cancer
Sale!
![]()
BEVICRA 400MG
2-8* C
BEVACIZUMAB CONCENTRATE FOR SOLUTION 400MG/16ML
| MRP | : |
|
| Price | : | ₹13,500.00 |
| You Save | : | ₹16,500.00 (55%) |
1 Vial(s) Of 16ml
Bevicra 400 mg Injection is a monoclonal antibody utilized for the treatment of metastatic breast cancer, non-small cell lung cancer, kidney cancer, cervical cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, as well as colon and rectal cancer. Cancer is characterized by the uncontrolled growth and reproduction of cells in a specific area of the body. It can originate in one part and subsequently spread to other regions, a process known as metastasis.
Bevicra 400 mg Injection contains ‘Bevacizumab’, which targets vascular endothelial growth factor (VEGF) present on the lining of lymphatic and blood vessels. VEGF promotes the formation of blood vessels within tumors, supplying them with oxygen and nutrients. By inhibiting vascular endothelial growth factor, the flow of oxygen and nutrients to the tumor is restricted, leading to its reduction or halting its growth. Therefore, it plays a crucial role in cancer treatment.
Administration of Bevicra 400 mg Injection will be carried out by a healthcare professional; self-administration is not advised. Your doctor will determine the appropriate dosage and duration based on your medical condition. In certain instances, Bevicra 400 mg Injection may lead to side effects such as loss of appetite, constipation, fever, nosebleeds, alterations in speech, and changes in taste. Most of these side effects are temporary and do not necessitate medical intervention. However, if they persist or worsen, it is important to consult your doctor.
Avoid using Bevicra 400 mg Injection if you are pregnant. It is essential to employ effective contraception during treatment and for six months following the final dose. Bevicra 400 mg Injection may induce drowsiness and fainting; therefore, refrain from driving while undergoing treatment. Additionally, do not breastfeed during the treatment period and for six months after the last dose of Bevicra 400 mg Injection. Keep your doctor updated about your health status and any medications you are taking to prevent potential side effects.
